Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.41 |
| ▸ | NOS1 | P29475 | 1/20 | 0.41 |
| ▸ | NOS2 | P35228 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 3/20 | 0.39 |
| ▸ | CES1 | P23141 | 2/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 5/20 | 0.35 |
| ▸ | ACHE | P22303 | 5/20 | 0.35 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.35 |
| ▸ | GRIN2A | Q12879 | 4/20 | 0.35 |
| ▸ | CD44 | P16070 | 1/20 | 0.34 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.34 |
| ▸ | BAD | Q92934 | 1/20 | 0.34 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19830022 | 0.95 | NOS3 (0.45) | NOS3NOS1NOS2DRD4POLB | |
| SCHEMBL24428893 | 0.76 | CES1 (0.39) | NOS3NOS1NOS2DRD4POLB | |
| SCHEMBL20112700 | 0.76 | CES1 (0.52) | NOS3NOS1NOS2DRD4CES1 | |
| SCHEMBL13091621 | 0.76 | NOS3 (0.39) | NOS3NOS1NOS2DRD4POLB | |
| SCHEMBL29573959 | 0.76 | NOS3 (0.39) | NOS3NOS1NOS2CES1PARP1 | |
| SCHEMBL20634317 | 0.76 | NOS3 (0.39) | NOS3NOS1NOS2CES1PARP1 | |
| SCHEMBL15471189 | 0.76 | PNMT (0.43) | NOS3NOS1NOS2PARP1BCHE | |
| SCHEMBL25242966 | 0.76 | HTR1D (0.43) | NOS3NOS1NOS2CES1PARP1 | |
| SCHEMBL31029287 | 0.76 | HTR1D (0.43) | NOS3NOS1NOS2CES1PARP1 | |
| SCHEMBL19475429 | 0.75 | CES1 (0.37) | NOS3NOS1NOS2DRD4CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12617802-B2 | Sulfonimidamide compounds as NLRP3 modulators | GENENTECH, INC. (US) | 2026-05-05 | — | — | US | disclosed |
| US-20230399319-A1 | Acylsulfamide Compound and Pharmaceutical Use Therefor | JAPAN TOBACCO INC. (JP) | 2023-12-14 | — | — | US | disclosed |
| US-20230399319-A1 | Acylsulfamide Compound and Pharmaceutical Use Therefor | JAPAN TOBACCO INC. (JP) | 2023-12-14 | — | — | US | disclosed |
| US-20230399319-A1 | Acylsulfamide Compound and Pharmaceutical Use Therefor | JAPAN TOBACCO INC. (JP) | 2023-12-14 | — | — | US | disclosed |
| US-20230159555-A1 | SULFONIMIDAMIDE COMPOUNDS AS NLRP3 MODULATORS | GENENTECH, INC. (US) | 2023-05-25 | — | — | US | disclosed |
| US-20230159555-A1 | SULFONIMIDAMIDE COMPOUNDS AS NLRP3 MODULATORS | GENENTECH, INC. (US) | 2023-05-25 | — | — | US | disclosed |
| US-20230159555-A1 | SULFONIMIDAMIDE COMPOUNDS AS NLRP3 MODULATORS | GENENTECH, INC. (US) | 2023-05-25 | — | — | US | disclosed |
| CN-115461120-A | Sulfonylimide compounds as NLRP3 modulators | 豪夫迈·罗氏有限公司 | 2022-12-09 | — | — | CN | disclosed |
| EP-4093509-A1 | SULFONIMIDAMIDE COMPOUNDS AS NLRP3 MODULATORS | F. Hoffmann-La Roche AG (CH) | 2022-11-30 | — | — | EP | disclosed |
| EP-4082614-A1 | ACYLSULFAMIDE COMPOUND AND PHARMACEUTICAL USE THEREFOR | Japan Tobacco Inc. (JP) | 2022-11-02 | — | — | EP | disclosed |
| CN-114829345-A | Acylsulfonamide compound and medicinal use thereof | 日本烟草产业株式会社 | 2022-07-29 | — | — | CN | disclosed |
| WO-2021150574-A1 | SULFONIMIDAMIDE COMPOUNDS AS NLRP3 MODULATORS | GENENTECH, INC. (US) | 2021-07-29 | — | — | WO | disclosed |
| WO-2021132577-A1 | ACYLSULFAMIDE COMPOUND AND PHARMACEUTICAL USE THEREFOR | 日本たばこ産業株式会社 | 2021-07-01 | — | — | WO | disclosed |
| WO-2021132577-A1 | ACYLSULFAMIDE COMPOUND AND PHARMACEUTICAL USE THEREFOR | 日本たばこ産業株式会社 | 2021-07-01 | — | — | WO | disclosed |
| WO-2017184624-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | IFM THERAPEUTICS, INC (US) | 2017-10-26 | — | — | WO | disclosed |
| US-3936293-A | PLANT GROWTH REGULATORS | CIBA-GEIGY CORPORATION (US) | 1976-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159555-A1 | SULFONIMIDAMIDE COMPOUNDS AS NLRP3 MODULATORS | NLRP3, NLRP1, PYCARD | NOS3 1355/4885NOS1 997/4885NOS2 1055/4885 |
| US-12617802-B2 | Sulfonimidamide compounds as NLRP3 modulators | NLRP3, NLRP1, PYCARD | NOS3 1579/4885NOS1 1384/4885NOS2 1410/4885 |
| US-20230399319-A1 | Acylsulfamide Compound and Pharmaceutical Use Therefor | NLRP3, NLRP1, NOD1 | NOS3 3183/4885NOS1 2771/4885NOS2 3271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.